The Analyst Landscape: 7 Takes On Avidity Biosciences
The Analyst Landscape: 7 Takes On Avidity Biosciences
分析師視角：對avidity biosciences的七種看法
In examining...In the preceding three months, 7 analysts have released ratings for Avidity Biosciences (NASDAQ:RNA), presenting a wide array of perspectives from bullish to bearish.
在過去的三個月中，有7位分析師發佈了對Avidity Biosciences (納斯達克：RNA) 的評級，呈現出從看好到看淡的各種觀點。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他們最近評級的精簡視圖，顯示了過去30天的不同情緒，並將其與前幾個月進行比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $47.14, a high estimate of $60.00, and a low estimate of $35.00. Witnessing a positive shift, the current average has risen by 20.87% from the previous average price target of $39.00.
通過他們對12個月目標價格的評估，分析師提供了更深入的見解，揭示了平均目標價爲$47.14，最高估價爲$60.00，最低估價爲$35.00。目前平均值已經比上一個平均目標價格高20.87%。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析師評級：詳細剖析
In examining...
通過...
登入免費觀看全文
登入/註冊